Embryonics

growth-positive

Embryonics, an Israel-based data-driven fertility company, has announced a partnership with Jaslok-FertilTree International Fertility Centre in India. The partnership aims to increase the success rate of fertility treatments in the Indian subcontinent. Embryonics has developed an assistive embryo selection tool called UBAR, which uses deep learning algorithms to predict implantation probability and assist in embryo selection. The company aims to reduce the number of IVF rounds and associated costs for women undergoing IVF. The partnership with Jaslok-FertilTree International is expected to modernize the fertility lab and bring AI-driven personalized medicine to the field of IVF. The collaboration aligns with the goals and vision of Dr. Firuza Parikh, a renowned fertility specialist in India. The article highlights the growing demand for IVF services and the need for innovative solutions to improve success rates.

growth-positive

Embryonics, an AI fertility company, is developing an algorithm to predict embryo-implanting probability during in vitro fertilization (IVF). The company aims to reduce the number of IVF rounds and costs associated with the process. A clinical study at the Nadiya Clinic of Reproductive Medicine has reported six pregnancies, with more participants awaiting test results. Embryonics plans to conduct a clinical trial in the United States and seeks approval from the U.S. Food and Drug Administration by the end of 2021. The IVF market is expected to double in the next five years, providing opportunities for fertility companies. Embryonics technology, called Ubar, uses geometric deep learning and also offers personalized hormonal treatments for IVF patients.

growth-positive

Israeli startup Embryonics has developed an AI algorithm to predict embryo implantation probability during in vitro fertilization (IVF). The company aims to reduce the number of IVF rounds and associated costs, which can range from $10,000 to $15,000 per cycle. Embryonics has conducted a pilot study with 11 women, with six successful pregnancies and five awaiting results. The global IVF market is expected to double in the next five years, presenting a significant growth opportunity for Embryonics. The company has received $4 million in seed funding and is awaiting regulatory approval in Europe to sell its software to fertility clinics. Embryonics also plans to expand into the US and work on improving hormonal stimulation protocols in collaboration with fertility clinics.

growth-positive

Israeli startup Embryonics, which uses AI and machine learning for fertility treatments, is exploring the use of its technology to diagnose and treat COVID-19 patients. The company has developed algorithms for embryo selection and personalized hormonal treatments in IVF, and now wants to apply geometric deep learning to predict the needs of COVID-19 patients. Embryonics is working with Shaare Zedek Medical Center in Jerusalem to access patient data and build predictive software. The startup aims to adapt its embryo-selecting algorithm to make predictions about COVID-19 patients outcomes and treatment recommendations. Embryonics has raised $4 million in seed funding and grants and is seeking FDA approval for its IVF software.